Sarah Vantassel, MD
Glaucoma Specialist · New York, NYNPI 1982966974
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $54,684 of the $75,585 with a category attached, or 72.3%. It is spread thinly across 12 manufacturers, the largest accounting for just 21.2%. Among glaucoma specialist clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 112 payments — averaging $674.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$16K
- NEW World Medical,inc.$14K
- Glaukos Corporation$13K
- Carl Zeiss Meditec, Inc.$11K
- Alcon Research LLC$7K
- Alcon$6K
- plus $10K from 6 others
What the payments were for
- Consulting fees$54,68472%
- Speaking & faculty fees$17,40023%
- Travel & lodging$590%
- Food & beverage$3,4425%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 46 | $16,029 |
| NEW World Medical,inc. | 18 | $13,619 |
| Glaukos Corporation | 11 | $12,588 |
| Carl Zeiss Meditec, Inc. | 8 | $10,825 |
| Alcon Research LLC | 6 | $7,348 |
| Alcon | 9 | $5,665 |
| Thea Pharma Inc. | 2 | $4,500 |
| Aerie Pharmaceuticals, Inc. | 4 | $1,781 |
| Tarsus Pharmaceuticals, Inc. | 3 | $1,660 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $1,300 |
| Aspira Women's Health Inc | 1 | $152 |
| Sight Sciences, Inc. | 1 | $118 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ahmed Glaucoma Valve$13,532
- DURYSTA$11,615
- Kahook Dual Blade$11,532
- Humphrey HFA$8,050
- XEN GLAUCOMA TREATMENT SYSTEM$5,935
- Clearpath$5,900
- Streamline$5,900
- CIRRUS HD-OCT$5,325
- Glaucoma Workplace$4,950
- Retina Workplace$4,950
- IYUZEH$4,500
- Rocklatan$3,414
- Rhopressa$3,414
- CLARUS 500$3,300
- Via360$3,100
- CLARUS$2,550
- iStent Trabecular Micro-Bypass Stent System$2,100
- Hydrus Microstent$2,028
- LUMIGAN$1,772
- SIMBRINZA$1,750
How this compares
$75,585 in reported general payments places this provider in the 95th percentile of 35 glaucoma specialist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 158 | $96,987 |
| XiidraLifitegrast | 79 | $94,696 |
| RestasisCyclosporine | 62 | $80,753 |
| RocklatanNetarsudil Mesylat/Latanoprost | 85 | $54,681 |
| CombiganBrimonidine Tartrate/Timolol | 83 | $34,640 |
| MieboPerfluorohexyloctane/Pf | 17 | $23,653 |
| Alphagan PBrimonidine Tartrate | 42 | $20,469 |
| RhopressaNetarsudil Mesylate | 48 | $18,797 |
| VyzultaLatanoprostene Bunod | 44 | $16,819 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 46 | $16,784 |
| AzoptBrinzolamide | 20 | $13,044 |
| Brimonidine Tartrate | 238 | $12,583 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 74 | $11,174 |
| Prednisolone Acetate | 219 | $10,304 |
| Cyclosporine | 17 | $9,188 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $16,029 | $232,850345 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $1,781 | $73,478133 claims |
| AlconSimbrinza, Azopt | $5,665 | $29,82866 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $1,300 | $2,90724 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 35 glaucoma specialist providers in New York.
Other glaucoma specialist in New York
- Janet SerleNew York$103K
- Sonya DharNew York$19K
- Yvonne OkakaNew York$5K
- Varun ReddyNew York$4K
- Eileen ChangNew York$3K
- Paul PetrakosNew York$3K
- Gerald SheppsNew York$3K
- Nehali NantiNew York$2K
- Johnny LiNew York$2K
- Louis PasqualeNew York$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.